Superselective intra-arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer
| Autor: | Kiviniemi H, Laitinen S, Sami Leinonen, Riitta Kantola, Tapani Tikkakoski, T. Siniluoto, Matti Kairaluoma, Jyrki Mäkelä |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Colorectal cancer Mitomycin medicine.medical_treatment Rectum Gastroenterology Metastasis Hepatic Artery Risk Factors Internal medicine medicine Humans Infusions Intra-Arterial Prospective Studies Survival rate Aged Aged 80 and over Chemotherapy Antibiotics Antineoplastic business.industry Liver Neoplasms Mitomycin C Cancer General Medicine Middle Aged Prognosis medicine.disease Surgery Survival Rate medicine.anatomical_structure Oncology Tumor progression Female Colorectal Neoplasms business Follow-Up Studies |
| Zdroj: | Journal of Surgical Oncology. 65:127-131 |
| ISSN: | 1096-9098 0022-4790 |
| Popis: | Background Mitomycin C has been found clinically useful in the treatment of colorectal cancer when administered via the hepatic artery. In a prospective therapeutic trial, we studied the effect of superselective intra-arterial chemotherapy with mitomycin C in patients with hepatic metastases from colorectal cancer. Methods Forty-six patients with hepatic metastases from colorectral cancer received intra-arterial chemotherapy with mitomycin C (SIAC) between 1981 and 1991. The results of a 5-year follow-up were compared with 46 control patients standardized by sex, age, and tumor distribution. Results The overall response rate to intra-arterial chemotherapy was 20%. The median survival time for responders was 26 months and that for nonresponders 12 months (P < 0.003). The median survival period after intra-arterial chemotherapy was 15 months, compared with 9 months in controls (P < 0.004). The cumulative 5-year survival rate was 6% for patients treated by SIAC and 5% for controls. Cessation of chemotherapy was necessary in 39 of the 46 patients: in 28 because of tumor progression, in 9 because of toxicity, in 1 because of catheterization difficulties, and in 1 because of patient refusal. Conclusions Superselective intra-arterial mitomycin C therapy had a poor effect on hepatic metastases from colorectal cancer because of the low response and long-term survival rates. J. Surg. Oncol. 1997;65:127–131. © 1997 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text